Drug Profile

EVOLVE 108

Alternative Names: EVOLVE-108

Latest Information Update: 21 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EvolveImmune Therapeutics
Developer AbbVie; EvolveImmune Therapeutics
Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
Mechanism of Action CD2 antigen stimulants; Immunologic cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

14 Jan 2026 EvolveImmune and AbbVie agree to co-develop EVOLVE 108 for Cancer (EvolveImmune pipeline, January 2026)
14 Jan 2026 Early research in Cancer in USA (Parenteral), prior to January 2026 (EvolveImmune pipeline, January 2026)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com